QTR Family Wealth LLC Has $716,000 Stock Position in Johnson & Johnson $JNJ

QTR Family Wealth LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 20.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,686 shares of the company’s stock after buying an additional 798 shares during the period. QTR Family Wealth LLC’s holdings in Johnson & Johnson were worth $716,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of JNJ. Highline Wealth Partners LLC lifted its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at about $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Bank of America increased their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Thursday, July 17th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Royal Bank Of Canada boosted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $181.40.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $185.98 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $186.59. The stock has a market capitalization of $447.91 billion, a P/E ratio of 19.89, a P/E/G ratio of 2.37 and a beta of 0.40. The business has a 50-day moving average price of $175.78 and a two-hundred day moving average price of $162.66.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.